Healthcare Review: Cryolife Inc, Vertex Pharmaceuticals, Zalicus, Actavis, Pfizer Print E-mail
By Staff and Wire Reports   
Tuesday, 29 October 2013 13:35
U.S. stocks advanced on Tuesday, as soft economic data supported expectations the U.S. Federal Reserve will keep its stimulus measures intact for several months, while gains in Pfizer and IBM helped the Dow. Economic data showed consumer spending rose in September, but auto sales fell, indicating sluggish economic growth in the third quarter. Other data showed consumer confidence fell sharply in October as a result of the partial government shutdown while producer prices unexpectedly fell in September, pointing to muted inflation.

Shares of Cryolife Inc. (NYSE:CRY) are up sharply on the heels of the company's Q3 beat.Net income for the quarter rose 106%, while product revenues jumped 11%.BioGlue revenues (which made up 80% of total product sales) rose 12% for the period. FY13 outlook: EPS of $0.58-0.60 on sales of $139-141M. $0.29/share is attributable to CRY's investment in Medafor, which C.R. Bard recently acquired. See: CRY makes nice profit on Medafor stake.

Wells Fargo is out defending Vertex Pharmaceuticals ($VRTX). The stock is trading notably lower after Incivek sales came in sharply below expectations for Q3. The company is cutting jobs related to the HCV drug. "Overall we did not see any major surprises on the call; we believe the continuing Incivek decline and cuts to the commercial team were mostly expected," analyst Brian Abrahams says, adding that the company may now be in a better position to focus on cystic fibrosis. Abrahams also sees "a reasonable probability that expected Q1 2014 data [on VX-135] in combo with daclatasvir (BMY) will demonstrate competitive SVRs."

For the second time in four sessions, Zalicus ($ZLCS) looks to be getting a lift from an SA contributor.Last time it was Jason Napodano, this time it's MarketScanners. The FDA's move to reclassify hydrocodone-based painkillers as Schedule II substances "is calling attention to ZLCS," the author says, before noting that ZLCS should perhaps be considered "a short-term" trade.

Actavis' ($ACT) Q3 prints in line as both revenue and adjusted earnings post double-digit growth.Adjusted gross margin rises 430 bps. Revenue growth by segment: Pharma, +69%; Specialty Brands, +27%; Distribution, +26%.FY13 outlook (including Warner Chilcott): Adjusted EPS of $9.26-9.39 on sales of $8.6B. Consensus is $8.35 on sales of $8.08B.FY14 outlook (including Warner Chilcott): Adjusted EPS of $12.25-13.

Pfizer ($PFE) net profit -19% to $2.59B.Revenue of $12.64B was down 2% on year.Changes FY EPS guidance to $2.15-2.20 from a prior forecast of $2.10-2.20 and vs Street expectations of 2.16. Adjusted revenues seen at $50.8-51.8B vs $50.8-52.8B prior and consensus of $51.45B.Repurchased $3.8B in shares. Revenue breakdown: Primary Care -10% to $3.26B; Emerging Markets +2% to $2.43B; Established Products -4% to $2.3B; Consumer Healthcare +1% to $788M; Oncology +24% to $407M.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter